Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Heidenreich

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
European Journal of Human Genetics : EJHG|February 13, 2014
Biallelic MUTYH mutations can mimic Lynch syndromeMonika Morak, Barbara Heidenreich, Gisela Keller, et al.
Oncotarget|February 25, 2016
Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcriptsHuaping Xie, P Sivaramakrishna Rachakonda, Barbara Heidenreich, et al.
Oncotarget|July 25, 2016
TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activationAndrelou F Vallarelli, P Sivaramakrishna Rachakonda, Jocelyne André, et al.
International Journal of Cancer|October 22, 2014
TERT promoter mutations in clear cell renal cell carcinomaIsmail Hosen, P Sivaramakrishna Rachakonda, Barbara Heidenreich, et al.
International Journal of Cancer|March 27, 2015
Mutations in TERT promoter and FGFR3 and telomere length in bladder cancerIsmail Hosen, P Sivaramakrishna Rachakonda, Barbara Heidenreich, et al.
Neuro-Oncology|August 21, 2014
TERT promoter mutations: a novel independent prognostic factor in primary glioblastomasMatthias Simon, Ismail Hosen, Konstantinos Gousias, et al.
Nature Communications|February 27, 2014
Telomerase reverse transcriptase promoter mutations in primary cutaneous melanomaBarbara Heidenreich, Eduardo Nagore, P Sivaramakrishna Rachakonda, et al.
Genes, Chromosomes & Cancer|September 12, 2018
Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma riskSivaramakrishna Rachakonda, Haiying Kong, Nalini Srinivas, et al.
Neuroradiology|September 13, 2017
New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastomaTunc F Ersoy, Vera C Keil, Dariusch R Hadizadeh, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2013
TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphismP Sivaramakrishna Rachakonda, Ismail Hosen, Petra J de Verdier, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
European Journal of Human Genetics : EJHG|February 13, 2014
Biallelic MUTYH mutations can mimic Lynch syndromeMonika Morak, Barbara Heidenreich, Gisela Keller, et al.
Oncotarget|February 25, 2016
Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcriptsHuaping Xie, P Sivaramakrishna Rachakonda, Barbara Heidenreich, et al.
Oncotarget|July 25, 2016
TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activationAndrelou F Vallarelli, P Sivaramakrishna Rachakonda, Jocelyne André, et al.
International Journal of Cancer|October 22, 2014
TERT promoter mutations in clear cell renal cell carcinomaIsmail Hosen, P Sivaramakrishna Rachakonda, Barbara Heidenreich, et al.
International Journal of Cancer|March 27, 2015
Mutations in TERT promoter and FGFR3 and telomere length in bladder cancerIsmail Hosen, P Sivaramakrishna Rachakonda, Barbara Heidenreich, et al.
Neuro-Oncology|August 21, 2014
TERT promoter mutations: a novel independent prognostic factor in primary glioblastomasMatthias Simon, Ismail Hosen, Konstantinos Gousias, et al.
Nature Communications|February 27, 2014
Telomerase reverse transcriptase promoter mutations in primary cutaneous melanomaBarbara Heidenreich, Eduardo Nagore, P Sivaramakrishna Rachakonda, et al.
Genes, Chromosomes & Cancer|September 12, 2018
Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma riskSivaramakrishna Rachakonda, Haiying Kong, Nalini Srinivas, et al.
Neuroradiology|September 13, 2017
New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastomaTunc F Ersoy, Vera C Keil, Dariusch R Hadizadeh, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2013
TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphismP Sivaramakrishna Rachakonda, Ismail Hosen, Petra J de Verdier, et al.
Pageof 3